Compared with the aspirin monotherapy group, patients receiving P2Y12 inhibitor monotherapy were older, less often male, and had a higher prevalence of cardiovascular comorbidities, including hypertension, diabetes mellitus, heart failure, prior MI, prior stroke, and chronic kidney disease; however, PCI for acute MI was more common in the aspirin monotherapy group (all p < 0.05; Supplement Table S2). Here, P2RY12 is linked to chronic kidney disease.